Lazio Innova
VC Fund
Rome, Italy
Lazio Innova is a venture capital firm with its headquarters in Rome in Italy. The firm provides services in areas such as credit support and guarantees, interventions in risk capital, internationalization services, promotion of business networks and services for the creation and enterprise development.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $27M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Lazio Innova invests in
Stages Lazio Innova invests in
Countries Lazio Innova invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $400k–$1.9M
- Grant
- $22k–$121k
- Pre-Seed
- $53k–$518k
Investment Focus
Industry
- Health Care 6 (18%)
- Software 5 (15%)
- Biotechnology 5 (15%)
- Artificial Intelligence 4 (12%)
- Medical 3 (9%)
Stage
- Seed 12 (35%)
- Pre-Seed 8 (24%)
- Grant 5 (15%)
- Series A 1 (3%)
- Funding Round 1 (3%)
Country
- Italy 24 (71%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrea Ciampalini
Founder & General Manager
|
Founder & General Manager | Total investments: 1 | Find email | |
|
Lorenzo De Fabio
Responsabile operativo Venture Capital
|
Responsabile operativo Venture Capital | Total investments: 0 | Find email | |
Michela Michilli
Head of Development and Promotion of new services in Spazio Attivo
|
Head of Development and Promotion of new services in Spazio Attivo | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
HEU
|
HEU is a legaltech company that automates and manages legal documents and allows users to edit and share them. | $1.3M / Seed / Jul 10, 2025 | |
GeneSys Bio
|
Antimicrobial Resistance (AMR) is a global health emergency projected to cause 10 million deaths annually by 2050. The crisis is fueled by slow, conventional diagnostics that take 3-5 days, forcing the empirical use of broad-spectrum antibiotics and accelerating the spread of superbugs.GeneSys Bio is commercialising a breakthrough solution: afully automated, sample-to-result molecular diagnostic platform that identifies infectious pathogens and their critical antibiotic resistance genes in under 30 minutes with >99% sensitivity and specificity. Our portable, laptop-sized device combines proprietary nucleic acid amplification with an AI-driven engine to deliver clear, actionable results directly to clinicians, veterinarians, and public health officials.Our platform is a modular "One Health" solution, adaptable via disease-specific kits for human, veterinary, and environmental applications. We are entering the market with a diagnostic for Urinary Tract Infections (UTIs), a condition affecting over 500 million people annually and a primary driver of antibiotic misuse. By enabling targeted therapy at the first patient encounter, our platform is set to reduce treatment costs by up to 13%, cut follow-up visits, and decrease mortality from complicated infections by 50%.GeneSys Bio is positioned to capture a significant share of this market by bridging the critical gap between speed, laboratory-grade accuracy, and accessibility. We are not just creating a device; we are building the future of decentralized infectious disease diagnostics to safeguard global health for generations to come | $107.1K / Grant / Jun 25, 2024 | |
|
GeneSys Bio
|
Antimicrobial Resistance (AMR) is a global health emergency projected to cause 10 million deaths annually by 2050. The crisis is fueled by slow, conventional diagnostics that take 3-5 days, forcing the empirical use of broad-spectrum antibiotics and accelerating the spread of superbugs.GeneSys Bio is commercialising a breakthrough solution: afully automated, sample-to-result molecular diagnostic platform that identifies infectious pathogens and their critical antibiotic resistance genes in under 30 minutes with >99% sensitivity and specificity. Our portable, laptop-sized device combines proprietary nucleic acid amplification with an AI-driven engine to deliver clear, actionable results directly to clinicians, veterinarians, and public health officials.Our platform is a modular "One Health" solution, adaptable via disease-specific kits for human, veterinary, and environmental applications. We are entering the market with a diagnostic for Urinary Tract Infections (UTIs), a condition affecting over 500 million people annually and a primary driver of antibiotic misuse. By enabling targeted therapy at the first patient encounter, our platform is set to reduce treatment costs by up to 13%, cut follow-up visits, and decrease mortality from complicated infections by 50%.GeneSys Bio is positioned to capture a significant share of this market by bridging the critical gap between speed, laboratory-grade accuracy, and accessibility. We are not just creating a device; we are building the future of decentralized infectious disease diagnostics to safeguard global health for generations to come | $21.7K / Grant / May 28, 2024 | |
Tech4All
|
We support the study by using AI. | $53.9K / Grant / Mar 20, 2024 | |
Joinrs
|
Joinrs is an AI based job platform where students, new graduates and junior talents start their careers. Companies post job offers and Joinrs AI reads and understands them, helping users better understand and apply for the most suitable opportunities.Joinrs has developed a platform that through AI models innovates the traditional job offer. Onone hand Joinrs is helping its users by simplifying and making it easier for them to visualize and select their job, on the other hand the platform allows companies to promote their brand through the diffusion of content and experiences on corporate culture, the selection process, and practical advice for talent.With hundreds of thousands of registered users and over 150 company clients, Joinrs has quickly become a prominent player in the market. Operating across the UK, Italy, Spain, Brazil and Portugal, our platform has garnered widespread adoption. We have recently closed a Seed Round investment of 1.7M€ that will help us accelerating our international expansion and consolidating our position in the Italian market.The Joinrs team is comprised of 25 fully committed individuals from several different countries and with offices in London, Milan and Rome. | $1.9M / Seed / Mar 15, 2024 | |
|
Tech4All
|
We support the study by using AI. | $21.6K / Grant / Dec 05, 2023 | |
Regensight
|
Regensight is the theranostic eye care health company. They design and manufacture transformative solutions for improving the quality of life of millions people globally. They introduce the theranostics paradigm for incision-free correction of visual disorders. | $409.1K / Grant / Nov 30, 2023 | |
GenomeUp
|
Rome-based healthtech startup that offers an ecosystem of AI-powered solutions for genetic analysis and clinical decision support for diseases. GenomeUp's mission is to be a global reference platform to support clinical decision-making for hospitals, laboratories, research centers, and pharmaceuticals to accelerate diagnosis times, improvepatient care and provide knowledge for health prevention, all in less than 24h. Based on these assumptions, the founders decided to evolve the startup and transform it into a Italian Benefit Corporation following the purpose of common benefit by acting responsibly, sustainably and transparently towards stakeholders, people, communities, the territory and the environment. | $1.2M / Convertible Note / Mar 15, 2023 | |
Ticketoo
|
Ticketoo is a fan community that provides a convenient, safe, and reliable way to buy and sell e-tickets for events in the secondary market. They are a fan-based community that sells and buys used tickets for concerts, sporting events, and other activities. | $106.9K / Pre-Seed / Feb 10, 2023 | |
Irreo
|
We enable agricultural and ornamental operators to automatize their irrigation system in a smart and efficient way to counter drought problems due to ongoing climate change. Launched in 2021, Irreo can provide dynamic and optimal irrigation scheduling using different types of satellite data without the need to install any sensors in the field. Inaddition, through our innovative control system and thanks to our field controllers, our customers can manage irrigation and fertigation directly from their smartphones. | $885.5K / Seed / Nov 23, 2022 | |
| See all 34 investments → | |||
Co-Investors
Digital Magics
5 deals together
Primo Capital
3 deals together
LVenture Group
3 deals together
Boost Heroes
2 deals together
Azimut Libera Impresa
1 deal together
CDP Venture Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Lazio Innova invest in?
Lazio Innova invests primarily in Health Care, Software and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 34 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Lazio Innova's check size?
Lazio Innova typically joins rounds of $400k–$1.9M at Seed, $22k–$121k at Grant and $53k–$518k at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lazio Innova participates in.
How do I contact Lazio Innova?
Public channels for Lazio Innova include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lazio Innova?
The team at Lazio Innova includes Andrea Ciampalini (Founder & General Manager), Lorenzo De Fabio (Responsabile operativo Venture Capital) and Michela Michilli (Head of Development and Promotion of new services in Spazio Attivo). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
